** Morningstar decreases fiscal 2026 gross margin forecast for Fisher & Paykel Healthcare FPH.NZ by roughly 230 basis points to 60.9% vs an estimated 62.3% in fiscal 2025
** Investment research firm trims the medical equipment maker's fiscal 2026 gross margin forecast as it estimates roughly 42% of FY revenue to be attributed to U.S., and about 60% of U.S. volumes are supplied from Mexico
** Maintains NZ$25 fair value estimate for co
** "Fisher's opportunity lies in increasing the utilization of nasal high-flow therapy for broader respiratory applications." — Morningstar
** Morningstar doesn't expect co's market position to be significantly affected as its internally developed proprietary
technology has helped maintain over 70% market share in humidified ventilation in hospitals & leading innovation in nasal high-flow therapy
** Co on Monday flagged its costs would likely increase in FY26 due to the U.S.'s introduction of new 25% tariffs on Mexico; such tariffs were later in the day paused for a month
** Stock down 8.6%, YTD
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.